Skip to content

Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?

Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01195077
Acronym
HIV
Enrollment
12
Registered
2010-09-03
Start date
2003-02-28
Completion date
2008-06-30
Last updated
2021-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV, Dietary intervention, Algae, HIV progression, Algae specific kind

Brief summary

Drawing inferences from epidemiologic studies of HIV/AIDS as well well as cell culture and animal studies of HIV inhibition by algae, we propose algal consumption as one unifying characteristic of countries with anomalously low rates. HIV/AIDS incidence and prevalence in Eastern Asia (\<1/10,000 adults in Japan and Korea), compared to Africa (≈1/10 adults) strongly suggest that differences in IV drug use and sexual behavior are insufficient to explain the 1000-fold variation. Even in Africa, AIDS/HIV rates vary. Spirulina is part of the daily diet for many people living in Chad, where prevalence of HIV has remained at less than 4% for more than 20 years. Average daily algae consumption in Asia and Africa ranges between 1 to 2 tablespoons (3 - 13 grams). HIV viral load is the main indicator of infection, however CD4 helper cell counts are most predictive of morbidity and mortality.We hypothesized that the consumption of algae could be important in diminishing the risk of HIV infection, and subsequent progression, possibly by enhancing the immune response.

Detailed description

Twelve HIV+ patients not on antiretroviral therapy were clinically evaluated and enrolled in the three-week study. Subjects received 10 algae capsules/d. Laboratory tests of CD4 counts and HIV RNA were performed at baseline, week 1, week 2, and week 3, and then once a month. Six subjects continued for between 4 and 14 months. In addition to CD4 lymphocyte counts and viral loads, subjects were evaluated monthly for Complete Blood Counts (CBC), Liver profile, Basic Metabolic Panel, and some subjects were evaluated for thyroid function and cholesterol. All subjects completed standard HIV Quality of Life questionnaires at each clinic visit.

Interventions

OTHERseaweed, spirulina, seaweed + spirulina

Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day. Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day. Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day. Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.

Sponsors

University of South Carolina
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of HIV * Able to swallow pills

Exclusion criteria

* Allergy to iodine/seafood * Thyroid disease * Not taking antiretroviral therapy

Design outcomes

Primary

MeasureTime frameDescription
Dietary algae influence on CD4 helper cells and HIV viral loadOnce a week for first 3 weeks, then once a monthThe first 6 subjects participated for 3 weeks. After analysis of the results, it was determined that there were no side effects and some indication of benefit. The next 6 subjects participated for up to 14 months.

Secondary

MeasureTime frameDescription
Would seaweed (Undaria) or spirulina or a combination of the two algae have more benefit?Participants were randomized to one of 3 treatments.The combination of the 2 algae appeared to have more benefit. However, the sample size was too small to make conclusions.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026